and the RNA-guided endonuclease Cas9 from the microbial CRISPR (clustered regularly interspaced short palindromic repeat) adaptive immune system 3, 4 . Genome-scale GOF screening approaches have largely remained limited to the use of cDNA library overexpression systems. However, it is difficult to capture the complexity of transcript isoform variance using these libraries, and large cDNA sequences are often difficult to clone into size-limited viral expression vectors. The cost and complexity of synthesizing and using pooled cDNA libraries have also limited their use. Novel technologies that overcome such limitations would enable systematic, genome-scale GOF perturbations at endogenous loci.
Programmable DNA-binding proteins have emerged as an exciting platform for engineering synthetic transcription factors for modulating endogenous gene expression [5] [6] [7] [8] [9] [10] [11] . Among the established custom DNA-binding domains, Cas9 is most easily scaled to facilitate genomescale perturbations 3, 4 owing to its simplicity of programming relative to zinc finger proteins and transcription activator-like effectors (TALEs). Cas9 nuclease can be converted into an RNA-guided transcription activator (dCas9-activator) via inactivation of its two catalytic domains 12, 13 and fusion to transcription activation domains. These dCas9-activator fusions targeted to the promoter region of endogenous genes can then modulate gene expression [7] [8] [9] [10] [11] . Although the current generation of dCas9-based transcription activators is able to achieve upregulation of some endogenous loci, the magnitude of transcriptional upregulation achieved by individual single-guide RNAs (sgRNAs) 12 typically ranges from low to ineffective [8] [9] [10] [11] . Tiling a given promoter region with several sgRNAs can produce more robust transcriptional activation [9] [10] [11] , but this requirement presents enormous challenges for scalability, and in particular for establishing pooled, genome-wide GOF screens.
To improve and expand the applications of Cas9, we recently undertook crystallographic studies to elucidate the atomic structure of the Cas9-sgRNA-target DNA tertiary complex 14 , thus enabling rational engineering of Cas9 and sgRNA. Here we report a series of structure-guided engineering efforts to create a potent transcription activation complex capable of mediating robust upregulation with a single sgRNA. Using this new activation system, we demonstrate activation of endogenous genes as well as non-coding RNAs, elucidate design rules for effective sgRNA target sites, and establish and apply genome-wide dCas9-based transcription activation screening to study drug resistance in a melanoma model. These results collectively demonstrate the broad applicability of CRISPR-based GOF screening for functional genomics research.
Structure-guided design of Cas9 complex
Transformation of the Cas9-sgRNA complex into an effective transcriptional activator requires finding optimal anchoring positions for the activation domains. Previous designs of dCas9-based transcription activators have relied on fusion of transactivation domains to either the amino or carboxy terminus of the dCas9 protein. To explore whether alternate anchoring positions would improve performance, we examined our previously determined crystal structure of the Streptococcus pyogenes dCas9(D10A/H840A) in complex with a single-guide RNA (sgRNA) and complementary target DNA 14 . We observed that the tetraloop and stem loop 2 of the sgRNA protrude outside of the Cas9-sgRNA ribonucleoprotein complex, with the distal 4 base pairs (bp) of each stem completely free of interactions with Cas9 amino acid side chains (Extended Data Fig. 1a ). On the basis of these observations, along with functional data demonstrating that substitutions and deletions in the tetraloop and stem loop 2 regions of the sgRNA sequence do not affect Cas9 catalytic function 14 ( Fig. 1a) , we reasoned that the tetraloop and stem loop 2 could tolerate the addition of protein-interacting RNA aptamers to facilitate the recruitment of effector domains to the Cas9 complex (Fig. 1b) .
We selected a minimal hairpin aptamer, which selectively binds dimerized MS2 bacteriophage coat proteins 15 , and appended it to the sgRNA tetraloop and stem loop 2 (Extended Data Fig. 1b) . We next tested whether MS2-mediated recruitment of VP64 to the tetraloop and stem loop 2 could mediate transcriptional upregulation more efficiently than a dCas9-VP64 fusion. As predicted, aptamer-mediated recruitment of MS2-VP64 to either tetraloop (sgRNA1.1) or stem loop 2 (sgRNA1.2) mediated three-and fivefold higher levels of Neurog2 upregulation than a dCas9-VP64 fusion (sgRNA 1.0), respectively. Recruitment of VP64 to both positions (sgRNA 2.0) resulted in an additive effect, leading to a 12-fold increase over dCas9-VP64 (sgRNA 1.0). Combining sgRNA 2.0 with dCas9-VP64 instead of dCas9 provided an additional 1.3-fold increase in Neurog2 upregulation (Fig. 1c) . We further compared sgRNA 2.0 to a sgRNA previously described bearing two MS2-binding stem loops at the 39 end (sgRNA 1 23MS2) 11 and found that sgRNA 2.0 drove 14-and 8.5-fold higher levels of transcription activation than sgRNA 1 23MS2 for ASCL1 and MYOD1, respectively (Fig. 1d) . This difference could be due to either improved positioning of MS2 stem loops or to dCas9 protection of internal MS2 stem loops from exonuclease degradation.
To further improve the potency of Cas9-mediated gene activation, we considered how transcriptional activation is achieved in natural contexts, where endogenous transcription factors generally act in synergy with co-factors 16 . We thus hypothesized that combining VP64 with additional, distinct activation domains could improve activation efficiency. We chose the NF-kB trans-activating subunit p65 that, while sharing some common co-factors with VP64, recruits a distinct subset of transcription factors and chromatin remodelling complexes. For example, p65 has been shown to recruit AP-1, ATF/CREB and SP1 (ref. 17) , whereas VP64 recruits PC4 (ref. 18) , CBP/p300 (ref. 19) , and the SWI/SNF complex 20 .
We then varied the effector domain fused to dCas9 or MS2. Heteroeffector pairing of dCas9 and MS2 fusion proteins (for example, dCas9-VP64 paired with MS2-p65 or dCas9-p65 with MS2-VP64) provided over 2.5-fold higher transcription activation for both ASCL1 and MYOD1 than homo-effector pairing (for example, dCas9-VP64 paired with MS2-VP64 or dCas9-p65 with MS2-p65) (Fig. 1e) . We further explored this concept of domain synergy by introducing the activation domain from human heat-shock factor 1 (HSF1) 21 as a third activation domain, and found that an MS2-p65-HSF1 fusion protein further improved transcriptional activation of ASCL1 (12%) and MYOD1 (37%) (Fig. 1f) . Additional modifications to the sgRNA as well as Cas9 protein, including varying the nuclear localization signal (NLS), provided only minor improvements (Extended Data Fig. 1c-e) . On the basis of these collective results, we concluded that the combination of sgRNA 2.0, NLS-dCas9-VP64 and MS2-p65-HSF1 comprises the most effective transcription activation system, and designated it synergistic activation mediator (SAM). For simplicity, we will refer to sgRNA 2.0 as sgRNA in subsequent discussions, unless noted otherwise.
Design rules for efficient sgRNAs
To evaluate thoroughly the effectiveness of SAM for activating endogenous gene transcription, we chose 12 genes that were previously found by several groups to be difficult to activate using dCas9-VP64 and individual sgRNA 1.0 guides 8, 10, 11 . For each gene, we selected 8 sgRNA target sites spread across the proximal promoter between 21,000 bp and the 11 transcription start site (TSS). For 9 out of 12 genes, the maximum level of activation achieved using dCas9-VP64 with any of the 8 sgRNA 1.0 guides was lower than twofold, while the remaining three genes (ZFP42, KLF4 and IL1B) were maximally activated between two-and fivefold (Fig. 2a) . In contrast, SAM stimulated transcription at least twofold for all genes and more than 15-fold for 8 out of 12 genes. SAM performed consistently better than sgRNA 1.0 1 dCas9-VP64 for all 96 guides, with a median gain of 105-fold greater upregulation across all 12 genes (activation by SAM divided by activation by sgRNA 1.0 1 dCas9-VP64).
Previous studies have demonstrated that the poor activation efficiency of single sgRNAs can be overcome by combining dCas9-VP64 with a pool of sgRNAs tiling the proximal promoter region of the target gene [9] [10] [11] . Therefore we compared the single sgRNA activation efficiency of SAM against dCas9-VP64 combined with a pool of 8 sgRNA 1.0 guides, all targeting the same gene. For 10 out of 12 genes, SAM with a single sgRNA performed more robustly than dCas9-VP64 with pools RESEARCH ARTICLE of 8 sgRNA 1.0 guides (Fig. 2b) . Additionally, inclusion of a third activation domain, MS2-p65-HSF1 or MS2-p65-MyoD1, outperformed MS2-p65 alone (Extended Data Fig. 2a) .
Next, we sought to determine factors that contribute to inter-and intragenic variability of activation efficiency by different sgRNAs. For inter-gene variability, differences in activation magnitudes could be due to epigenetic factors and/or variation in basal transcription levels. We were thus interested in correlating basal transcription with the level of transcription activation achieved using SAM. Using the relative transcriptional levels of target genes in control samples, we observed a highly significant correlation between the inverse of basal transcript level and the fold upregulation achieved using SAM ( Fig. 2c ; r 5 0.94, P , 0.0001). This suggests that the basal expression level of each gene largely determines the level of activation.
To study the intragenic variability of SAM activity, we aggregated the activation data for all 96 guides and found the distance between the guide RNA target site and the TSS to be the strongest predictor of activation efficiency ( Fig. 2d ; r 5 0.67, P , 0.0001). For all genes, the highest levels of activation were consistently achieved by targeting within the 2200 bp to 11 bp window. This simple design guideline can inform the selection of efficient sgRNAs for gene activation.
We also sought to test whether SAM is able to activate non-coding elements in addition to protein-coding genes. We chose a diverse set of 6 lincRNAs and found that SAM mediated significant upregulation of each target (Fig. 2e) , with MS2-p65-HSF1 or MS2-p65-MyoD1 leading to the highest levels of activation for each lincRNA (P , 0.01) (Extended Data Fig. 3 ). We also examined the effect of the most potent sgRNA for each lincRNA on the transcription of the nearest coding gene. Of all sgRNAs tested, only the sgRNA targeting HOTTIP-the only sgRNA located within 500 bp of the neighbouring gene's TSS-led to significant activation of its neighbour (Extended Data Fig. 2b ).
Multiplex gene activation
The ability to simultaneously modulate gene expression at multiple loci would allow for a better understanding of complex genetic and regulatory networks. Using sets of two to ten sgRNAs, we observed successful activation of all target genes (.twofold) within all sgRNA combinations (Fig. 3a, b and Extended Data Fig. 4 ). As expected, most genes (excluding IL1R2) exhibited a decrease in the amount of upregulation achieved when concurrently targeted with 9 other genes. Interestingly, the relative activation levels of each gene changed between multiplex activation and single-gene activation experiments (Fig. 3a, b) .
We asked if reduced activation of targets during multiplexing was due to the reduced amounts of sgRNA or SAM protein components. Surprisingly, diluting the sgRNA expression plasmid by tenfold in singlegene activation experiments did not reduce activation for all genes (Fig. 3c) . We found that genes whose levels of activation are reduced upon sgRNA dilution also exhibited dampened levels of activation when multiplexed ( Fig. 3d ; r 5 0.94, P , 0.001). In contrast, the activation efficiency of SAM was generally unperturbed by dilution of its protein components (dCas9-VP64 and MS2-p65-HSF1) (Extended Data Fig. 5 ). Activation efficiency remained stable particularly when all three components were diluted, retaining on average 90% activation efficiency across a 50-fold dilution range (Extended Data Fold activation 
Simultaneous activation of 10 genes by 10 sgRNAs Activation of individual genes by a single sgRNA 
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was particularly promising for genome-scale pooled screening applications, which rely on single-copy lentiviral integration.
Specificity of SAM-mediated activation
An important consideration for SAM use is its targeting specificity. Recent analysis of genome-wide dCas9-binding revealed significant concentration-dependent off-target binding 22 , yet its effect on the specificity of transcription modulation remains unclear. To assess SAM specificity, we chose HBG1/2 as our target gene, reasoning that globin genes would have few downstream targets that could confound our specificity analysis. We found that SAM specifically activated both HBG1 and HBG2 isoforms (P , 0.05, t-test after 0.01 false discovery rate (FDR) correction), which share the same TSS (Fig. 4 and Extended Data Fig. 6 ). We also tested two additional non-targeting sgRNAs with guide sequences that do not share perfect homology with the human genome. For all sgRNAs, we found only two additional genes, S100A1 and CYB5R2, to be differentially expressed (P , 0.05, t-test after 0.01 FDR correction for multiple hypothesis testing) compared with green fluorescent protein (GFP)-expressing control (Extended Data Fig. 6 ) for both non-targeting guides. These results suggest that SAM-mediated gene activation is specific with minimal off-target activity.
Genome-scale gene activation screen
The ability to activate target genes using individual sgRNAs greatly facilitates the development of pooled, genome-scale transcriptional activation screening. To develop a SAM-based screening system, we generated lentiviral expression vectors that are able to drive robust transcription activation at low multiplicity of infection (MOI) (Extended Data Fig. 7a, b) . Using this lentiviral system, we generated a genome-scale sgRNA library consisting of 70,290 guides, targeting every coding isoform from the RefSeq database (23,430 isoforms). For each gene, three sgRNAs were chosen to target sites within 200 bp upstream of the TSS, which was previously determined to provide more efficient activation ( Fig. 2d and  Fig. 5a ).
Previously we applied genome-scale CRISPR knockout (GeCKO) screening 3 in A375 (BRAF(V600E)) melanoma cells to identify LOF mutations capable of mediating resistance against the BRAF inhibitor PLX-4720. Here we sought to use the new SAM sgRNA library to identify a complementary set of GOF changes that can confer BRAF inhibitor resistance (Fig. 5a) .
We found that at 14 days post drug treatment, the sgRNA distribution was significantly different between cells treated with PLX-4720 and with vehicle, with the majority of sgRNAs exhibiting a reduced representation and a small set of guides showing high enrichment in PLX-4720-treated cells (Fig. 5b and Extended Data Fig. 7c ). For a number of gene targets, multiple sgRNAs targeting the same gene were enriched in PLX-4720-treated cells (Fig. 5c ) and the 10 most significant hits were distributed throughout the genome ( Fig. 5d and Extended Data Fig. 7d ). The significance of the P values of our top 100 hits determined by RNAi gene enrichment ranking (RIGER) (Supplementary Tables 1 and 2 ) was comparable to those observed for GeCKO screening 3 (Fig. 5e) . In addition, for the top 10 shared hits between two independent screens (zeocin and puromycin selection for sgRNA expression), the fraction of effectively enriched guides per gene (present in the top 5% of all guides) was very high with 97% for zeocin and 81% for puromycin (89% 6 10.7% overall, compared to 78% 6 27% for the top 10 GECKO hits, Fig. 5f and Extended Data Fig. 7e ).
Our screen results highlight a number of gene candidates that both confirm known PLX-4720 resistance pathways and suggest new mechanisms (Extended Data Fig. 7f) . First, reactivation of the ERK pathway RESEARCH ARTICLE is one of the main known resistance mechanisms 23, 24 , and two of our screening hits, BCAR3 and EGFR, probably modulate downstream and upstream nodes of this pathway, respectively 25, 26 . EGFR has been previously validated as a mediator of resistance to PLX-4720 through PI3K-AKT, in addition to ERK 26, 27 . These two pathways are thought to be alternative routes of PLX-4720 resistance 24, 28, 29 . Furthermore, four out of the top 10 hits from our screen belong to the family of G-proteincoupled receptors (GPCRs: GPR35, LPAR1, LPAR5 and P2RY8), which emerged as the top-ranked protein class conferring resistance to multiple MAP kinase inhibitors in melanoma cells in a recent screen using cDNA overexpression 30 . GPCRs signal through multiple downstream pathways including ERK and AKT as well as cAMP-PKA 31, 32 . The final class of protein candidates from our screen belongs to the ITG receptor family, which is thought to interact with RTK and activate both ERK and AKT pathways 33, 34 . To verify the results from the PLX-4720 resistance screen, we validated each of the top 13 genes. All sgRNAs from the screen that targeted these 13 genes conferred PLX-4720 resistance when individually expressed in A375 along with SAM ( Fig. 6a and Extended Data Fig. 8a ). We also verified that SAM was able to facilitate robust increase in target transcript ( Fig. 6a and Extended Data Fig. 8b ) and protein levels (Fig. 6a) . Since 5 of our top candidates from the pooled SAM screen overlapped with hits from a previously conducted arrayed cDNA screen 30 (Extended Data Fig. 8c) , we compared the relative efficacy of cDNA overexpression with SAM-mediated transcription activation. Interestingly, for these 5 targets, SAM led to at least similar levels of PLX-4720 resistance when compared with corresponding cDNA overexpression conditions (Extended Data Fig. 8a ), despite cDNA leading to higher transcript levels (Extended Data Fig. 8d) . Furthermore, we found that, for most genes, the levels of PLX-4720 resistance mediated by all three sgRNAs were comparable (Extended Data Fig. 8e) .
In addition to validating our top screening hits through individual sgRNA or cDNA overexpression, we analysed the expression profile of our screening hits using four different data sets (CCLE 35, 37 , TCGA: https://tcga-data.nci.nih.gov/tcga/, short-term melanoma cultures 36 , and pre/post treatment patient samples 38 ). As shown previously 39 , a distinct transcriptional state defines BRAF-inhibition sensitive and resistant states as described by activation of endogenous MITF/associated markers (for example, PMEL) and NF-kB-pathway activity/associated markers (for example, AXL), respectively ( Fig. 6b and Extended Data Fig. 9b ). Based on short-term melanoma data 36, 39 , we found that the expression of our top screening hits was significantly increased in the resistant state. Correspondingly, a gene expression signature based on the top screening hits (see Methods) correlated with a BRAF-inhibitor resistance state as defined previously 39 ( Fig. 6b ; total overlap, P , 0.0001). Further analysis performed using the CCLE, TCGA and pre/post treatment data set also revealed similar correlations (Extended Data Fig. 9 ).
Discussion
In summary, we have taken a structure-guided approach to design a dCas9-based transcription activation system for achieving robust, single sgRNA-mediated gene upregulation. By engineering the sgRNA to incorporate protein-interacting aptamers, we assembled a synthetic transcription activation complex consisting of multiple distinct effector domains modelled after natural transcription activation processes. Here we have shown that the SAM system is robust, specific, and can facilitate genomescale gain-of-function screening when combined with a compact pooled sgRNA library. Our SAM-mediated screens exhibited a high degree of consistency and validation, with .80% effectively enriched guides per gene hit, and 100% validation of the top 10 hits.
Future engineering of the Cas9 complex based on structural information 14, 40 will further expand the Cas9 toolbox 41 . Additional developments of the SAM system may be able to take advantage of the modularity and customizability of the sgRNA scaffold to establish a series of sgRNA scaffolds bearing different aptamers for recruiting distinct types of effectors in an orthogonal manner. For instance, replacement of the MS2 stem loops with PP7-interacting stem loops may be used to recruit repressive elements, potentially enabling multiplexed bidirectional transcriptional control.
Although we have taken initial steps towards defining selection rules for potent sgRNAs, future studies will reveal additional selection criteria that are critical for guide efficacy, such as sequence-intrinsic properties (Extended Data Fig. 10a-d) . Applications of dCas9-based transcription modulators in positive and negative selection screens (Extended Data  Fig. 10e, f) 42 will enable the dissection of many types of genetic elements, ranging from protein-coding genes to non-coding lincRNA elements. Furthermore, combining wild-type Cas9-mediated genome modifications with SAM-mediated recruitment of epigenetic modifiers will constitute powerful approaches for studying genome organization and regulation in diverse biological processes.
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Sequences. DNA sequences for SAM components and sgRNA scaffolds are provided in Supplementary Sequences. sgRNA target sequences for characterization and optimization of SAM are listed in Supplementary Table 4 . Transient transfection experiments. Neuro-2a cells (Sigma-Aldrich) were grown in media containing 1:1 ratio of OptiMEM (Life Technologies) to high-glucose DMEM with GlutaMAX and sodium pyruvate (Life Technologies) supplemented with 5% HyClone heat-inactivated FBS (Thermo Scientific), 1% penicillin/streptomycin (Life Technologies), and passaged at 1:5 every 2 days.
HEK293FT cells (Life Technologies) were maintained in high-glucose DMEM with GlutaMAX and sodium pyruvate (Life Technologies) supplemented with 10% heat-inactivated characterized HyClone fetal bovine serum (Thermo Scientific) and 1% penicillin/streptomycin (Life Technologies). Cells were passaged daily at a ratio 1:2 or 1:2.5. For gene activation experiments, 20,000 HEK293FT cells per well were plated in 100 ml media in poly-D-lysine-coated 96-well plates (BD BioSciences). 24 h after plating, cells were transfected with a 1:1:1 mass ratio of sgRNA plasmid with gene-specific targeting sequence or pUC19 control plasmid:MS2-effector plasmid or pUC19:dCas9 plasmid, dCas9-effector plasmid or pUC19.
A total plasmid mass of 0.3 mg per well was transfected using 0.6 ml per well of Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions. Culture medium was changed 5 h after transfection. 48 h after transfection, cell lysis and reverse transcription were performed using a Cells-to-Ct kit (Life Technologies). Relative RNA expression levels were quantified by reverse transcription and quantitative PCR (qPCR) using TaqMan qPCR probes (Life Technologies, Supplementary Table 5 ) and Fast Advanced Master Mix (Life Technologies). qPCR was carried out in 5 ml multiplexed reactions and 384-well format using a LightCycler 480 Instrument II. Data was analysed by the DDC t method: target C t values (FAM dye) were normalized to GAPDH C t values (VIC dye), and fold changes in target gene expression were determined by comparing to GFP-transfected experimental controls. Lentivirus production. HEK293T cells (Life Technologies) were cultured as described above for HEK293FT cells. 1 day before transfection, cells were seeded at ,40% confluency (12 3 T225 flasks for library scale production, 1 3 T25 flask for individual guide production). Cells were transfected the next day at ,80-90% confluency. For each flask, 10 mg of plasmid containing the vector of interest, 10 mg of pMD2.G and 15 mg of psPAX2 (Addgene) were transfected using 100 ml of Lipofectamine 2000 and 200 ml Plus Reagent (Life Technologies). 5 h after transfection the media was changed. Virus supernatant was harvested 48 h post-transfection, filtered with a 0.45-mm PVDF filter (Millipore), aliquoted, and stored at 280 uC. Lentiviral transduction. A375 cells (Sigma) were cultured in RPMI 1640 (Life Technologies) supplemented with 10% FBS (Seradigm) and 1% penicillin/streptomycin (Life Technologies) and passaged every other day at a 1:4 ratio. Cells were transduced with lentivirus via spinfection in 12-well plates. 3 3 10 6 cells in 2 ml of media supplemented with 8 mg ml 21 polybrene (Sigma) were added to each well, supplemented with lentiviral supernatant and centrifuged for 2 h at 1,000g. 24 h after spinfection, cells were detached with TrypLE (Life Technologies) and counted. Cells were replated at low density (7.5 3 10 6 cells per T225 Flask) and a selection agent was added either immediately (zeocin, blasticidin and hygromycin, all Life Technologies) or 3 h after plating (puromycin). Concentrations for selection agents we determined using a kill curve: 0.5 mg ml 21 puromycin, 200 mg ml 21 zeocin, 10 mg ml 21 blasticidin, and 300 mg ml 21 hygromycin. Media was refreshed on day 2 and cells were passaged every other day starting on day 4 after replating. The duration of selection was 4 days for puromycin and 7 days for zeocin, hygromycin and blasticidin. Lentiviral titres were determined by spinfecting cells with 6 different volumes of lentivirus ranging from 0 to 600 ml and counting the number of surviving cells after a complete selection (3-6 days). Design and cloning of SAM library. RefSeq coding gene isoforms with a unique TSS (total of 23,430 isoforms) were targeted with three guides each for a total library of 70,290 guides (Supplementary Table 6 ). Guides were designed to target the first 200 bp upstream of each TSS and subsequently filtered for GC content .25% and minimal overlap of the target sequence. After filtering, the remaining guides were scored according to predicted off-target matches as described previously 43 , and three guides with the best off-target scores were selected. Cloning of the SAM sgRNA libraries was performed as previously described 3 with a minimum representation of 100 transformed colonies per guide. Depletion and PLX-4720 screen. A375 cells stably integrated with SAM Cas9 and effector components were transduced with SAM sgRNA libraries as described above at an MOI of 0.2, with a minimal representation of 500 transduced cells per guide. Cells were maintained at .500 cells per guide during subsequent passaging. At 7 days post infection (DPI) (complete selection, see above), cells were split into vehicle (DMSO) and PLX-4720 conditions (2 mM PLX-4720 dissolved in DMSO, Selleckchem). Cells were passaged every 2 days for a total of 14 days of drug treatment.
.500 cells per guide were harvested as a baseline at 3 DPI (4 days before treatment) and at 21 DPI (after 14 days of treatment) for gDNA extraction. Genomic DNA was extracted using the Zymo Quick-gDNA midi kit (Zymo Research PCR products from all 96 reactions were pooled, purified using Zymo-Spin V with Reservoir (Zymo research) and gel extracted using the Zymoclean Gel DNA Recovery Kit (Zymo research). Resulting libraries were deep-sequenced on Illumina MiSeq and HiSeq platforms with a total coverage of .35 million reads passing filter per library. NGS and screen hits analysis. NGS data were de-multiplexed using unique index reads. Guide counts (Supplementary Table 7) were determined based on perfectly matched sequencing reads only. For each condition, guide counts were normalized to the total number of counts per condition, and log 2 counts were calculated based on these values. Ratios of counts between conditions were calculated as log 2 ((count 1 1 1)/(count 2 1 1)) based on normalized counts.
RIGER analysis was performed using GENE-E based on the normalized day 14 log 2 ratios (PLX-4720/DMSO) averaged over two independent infection replicates. All RIGER analysis used the Kolmogorov-Smirnov method as described previously 44 , except for Fig. 6c , where the weighted average method was used in order to enable comparison to GeCKO values determined by that method. Gene expression and pharmacological validation analysis. Gene expression data (CCLE, TCGA, short-term cultures, patient melanoma biopsies) and pharmacological data (CCLE, short-term cultures) were analysed to better understand the biological relevance of the top gene hits from the SAM screens. In the CCLE data set 35 , gene expression data (RNA-sequencing, GCHub: https://cghub.ucsc.edu/datasets/ccle.html) and pharmacological data (activity area for MAPK pathway inhibitors) from BRAF(V600) mutant melanoma cell lines were used to compute the association between PLX-4720 resistance and the gene expression of each of the top hits. Additionally, gene expression signatures comprised of the top hits were generated using single-sample Gene Set Enrichment Analysis (ssGSEA) 45 , and the associations between PLX-4720 resistance and these signatures were computed.
Gene expression data (Affymetrix GeneChip HT-HGU133) and PLX-4720 pharmacological data (GI 50: half-maximal growth inhibition concentration; only for a subset of the samples) from short term melanoma cultures (STC) 36 were also used for plotting the gene expression of top hits and their ssGSEA signature scores. Expression data for the STC samples were collapsed to maximum probe value per gene and pre-processed using robust spline normalization.
Gene expression (RNA-sequencing) and genotyping data were collected from 113 BRAF(V600)-mutant primary and metastatic patient tumours from The Cancer Genome Atlas (https://tcga-data.nci.nih.gov/tcga/) and these data were similarly used for determining the association between resistance and the expression of top hits/ssGSEA signature scores. Because pharmacological data was not available for the STCs (only a subset had PLX-4720 data) and the TCGA melanoma samples, a transcriptional state was plotted using marker genes and signatures 39 in order to identify samples resistant to BRAF-inhibition.
Gene expression data from 13 patients with BRAF(V600E) melanomas 38 was used for analysing the relationship between resistance and the expression of our top hits/ssGSEA signature scores. Because all the post-treatment tumours were resistant and not every sample had a paired on-treatment biopsy, we decided to order the samples by MITF expression in the pre-treatment samples to reflect the original PLX-4720 sensitivity state of the tumours. We then used the expression data in the post-treatment resistant tumours to plot the expression of top hits/ ssGSEA signature scores. We also calculated the log 2 -fold change between each patient's post/pre paired samples and determined the number of patients that had at least a log 2 -fold change of 2 per top screen hit. Single sample gene set enrichment analysis. While there was a significant association between the overexpression of some of our top individual SAM screen hits and resistance in three external cancer data sets, we sought a more robust scoring system independent of any single gene. Gene expression signatures were generated based on the set of top hits from each of the two SAM screens and for the overlap between them. Using single-sample Gene Set Enrichment analysis (ssGSEA), a score was generated for each sample that represents the enrichment of the SAM screen gene expression signature in that sample and the extent to which those genes are coordinately up-or downregulated. Additionally, signature gene sets from the Molecular Signature Database (MSigDB) 46 were used in order to fully map the ARTICLE RESEARCH transcriptional BRAF-inhibitor resistant/sensitive states in the short-term culture and TCGA data sets as previously described 39 . Information coefficient for measuring associations in external data sets. To measure correlations between different features (signature scores, gene expression, or drug-resistance data) in the external cancer data sets, an information-theoretic approach (Information Coefficient; IC) was used and significance was measured using a permutation test (n 5 10,000), as previously described 39 . The IC was calculated between the feature used to sort the samples (columns) in each data set and each of the features plotted in the heatmap (pharmacological data, gene expression, and signature scores). sgRNA sequence analysis. Depletion for each sgRNA was calculated as the ratio of counts (see ''NGS and screen hits analysis'') between day 3 and day 21. The sgRNAs corresponding to genes with significant depletion (P , 0.05 by RIGER analysis) in sgRNA-Puro and sgRNA-Zeo libraries were selected for analyses. These sgRNAs were analysed for nucleotide occurrence in the sgRNA sequence, distance from TSS, and guide strand relative to transcript orientation. For each variable, the correlation and significance with the sgRNA ratio was calculated by ordinary least squares linear regression. PLX-4720 survival assay. A375 cells stably integrated with dCas9-VP64 and MS2-p65-HSF1 were transduced with individual guides from the top screening hits of the Zeocin and Puromycin screens (13 genes total, 3 sgRNAs per gene) as well as available cDNA at an MOI of ,0.2 as described above. Cells were selected for guide expression with Zeocin (Life Technologies) for 5 days and replated at low density (3 3 10 3 cells per well in a 96-well plate). A375 cells and A375 cells expressing dCas9-VP64 and MS2-p65-HSF1 were plated as controls. Different concentrations of PLX-4720 (2 mM, 0.5 mM, 0.15 mM) or vehicle (DMSO) were added 3 h after plating. Cells were treated with PLX-4720 for 4 days before cell viability was measured using CellTiter-Glo Luminescent Cell Viability Assay (Promega). For qPCR quantification of target gene upregulation, cells were also plated at 5 DPI (3 3 10 4 cells per well in a 96-well plate) and harvested for mRNA 24 h after plating. Western blot. Protein lysates were prepared with RIPA lysis buffer (Cell Signaling Technologies) containing a protease inhibitor cocktail (Roche). Samples standardized for protein with the Pierce BCA protein assay (Thermo Scientific) were boiled at 95 uC for 5 min under reducing conditions (except for GPR35 samples, which were incubated at 37 uC for 30 min). After denaturation, samples for probing proteins with lower or higher molecular weight were separated by 10-20% or 4-15% Criterion Tris-HCl gels (Bio-Rad) and electrotransferred onto a 0.2-mm or 0.45-mm polyvinylidene difluoride membrane (Millipore), respectively. Blots were blocked with 5% BLOT-QuickBlocker (VWR) and probed with different primary antibodies (anti-EGFR (rabbit polyclonal, SC-03, Santa Cruz Biotechnology, 1:1,000 dilution), anti-PCDH7 (rabbit polyclonal, HPA011866, Sigma-Aldrich, 1:1,000 dilution), anti-ITGB5 (rabbit polyclonal, SC-14010, Santa Cruz Biotechnology, 1:500 dilution), anti-ARHGEF1 (rabbit polyclonal, 11363-1-AP, Proteintech, 1:5,000 dilution), anti-BCAR3 (rabbit polyclonal, A301-671A, Bethyl Laboratories, 1:2,000 dilution), anti-GPR35 (rabbit polyclonal, 10007660, Cayman Chemical, 1:1,000 dilution), anti-TFAP2C (rabbit polyclonal, 2320, Cell Signaling Technology, 1:1,000 dilution, 2.5% bovine serum albumin, Sigma-Aldrich)) in 2.5% BLOT-QuickBlocker (VWR) unless noted otherwise overnight at 4 uC. Blots were then incubated with secondary antibody HRP-conjugated goat anti-rabbit IgG (7074, Cell Signaling Technology, 1:1,000 dilution) and HRP-conjugated GAPDH (rabbit monoclonal, 3683, Cell Signaling Technology, 1:2,000 dilution) in 2.5% BLOT-QuickBlocker (VWR) for 1 h at room temperature. Proteins with molecular weights similar to GAPDH (GPR35 and TFAP2C) were stripped with Restore Plus Western Blot Stripping Buffer (Thermo Scientific) before probing for GAPDH. SuperSignal West Pico and Femto Chemiluminescent Substrates (Thermo Scientific) were used for detection. RNA sequencing and data analysis. Samples harvested for RNA sequencing were prepped with TruSeq Stranded mRNA Sample Prep Kit (Illumina) and deepsequenced on the Illumina MiSeq platform (.9 million reads per condition). Bowtie2 47 index was created based on the human hg19 UCSC genome and known gene transcriptome, and paired-end reads were aligned directly to this index using Bowtie2 with command line options ''-q-phred33-quals -n 2 -e 99999999 -l 25 -I 1 -X 1000 -a -m 200 -p 4-chunkmbs 512''. Next, RSEM v1.27 48 was run with default parameters on the alignments created by Bowtie2 to estimate expression levels. RSEM's gene level expression estimates (tau) were multiplied by 1,000,000 to obtain transcript per million (TPM) estimates for each gene, and TPM estimates were transformed to log-space by taking log 2 (TPM11). The normalization between libraries was tested using an MA plot (mairplot function in Matlab V2013b). Genes were considered detected if their transformed expression level was equal to or above 1 (in log 2 (TPM11) scale). All genes detected in at least one library (out of three libraries per condition) were used to construct scatter plots comparing each of the six conditions to the control GFP condition, using the average across biological replicates with .80% alignment to the hg19 UCSC known gene transcriptome (log 2 (mean(TPM)11) value per gene).
To find differentially expressed genes, we performed Student's t-test on each of the six conditions against the GFP condition. The t-test was run on all genes that had expression levels above log 2 (TPM11).2.5 in at least two libraries. This threshold was chosen as the minimal threshold for which the number of detected genes across all libraries was constant. Only genes that were significant (P-value pass 0.01 FDR correction) and had at least 1.5-fold change were reported and visualized using a heat map.
Extended Data Figure 7 | Genome-scale lentiviral screen using puromycin-resistant SAM sgRNA library. a, Design of three lentiviral vectors for expressing sgRNA, dCas9-VP64, and MS2-p65-HSF1. Each vector contains a distinct selection marker to enable co-selection of cells expressing all three vectors. b, Lentiviral delivery of SAM components was tested by first generating 293FT cell lines stably integrated with dCas9-VP64 and MS2-p65-HSF1, and subsequently transducing these cells with single-gene targeting lentiviral sgRNAs at MOI ,0.2. Transcription activation efficiency is measured 4 days post sgRNA lentivirus transduction and selection with zeocin or puromycin. Activation is at least as effective as previously observed with transient transfection in all three cases. c, Box-plot showing the distribution of sgRNA frequencies at different time points post lentiviral transduction with the Puromycin library, after treatment with DMSO vehicle or PLX-4720. Two infection replicates are shown. d, Identification of top candidate genes using the RIGER P value analysis (KS method) based on the average of both infection replicates. Genes are organized by positions within chromosomes. e, Overlap between the top 20 hits from the zeocin and puromycin screens. Genes belonging to the same family are indicated by the same colour. There is a 50% overlap between the top hits of each screen as shown in the intersection of the Venn diagram. f, Relevant signalling pathways in BRAF inhibitor resistance. Reactivation of the Ras-ERK pathway as well as the parallel PI3K-Akt pathway have previously been implicated as two alternative resistance mechanisms to BRAF inhibitors 23, 24, [26] [27] [28] [29] . Both pathways have been described as stimulating proliferation and survival 49 . BAD, FOXO and p27 are common inhibited downstream targets 49 . Recently, stimulation of the cAMP-CREB pathway by GPCRs has been described as a potential additional resistance mechanism 30 . Top candidates from our screen are indicated in blue and putative connections to all three pathways are shown 25, 50, 51 . Candidates previously validated to mediate PLX-4720 resistance are underlined in green 26, 30 . COT and CREB are independently validated mediators of resistance 23, 30 . ARTICLE RESEARCH
